1. Jo, VY, Fletcher, CD. WHO Classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95-104.
Google Scholar | Crossref | Medline2. Zhou, M, Wang, H, Zeng, X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet (London, England). 2019;394(10204):1145-1158.
Google Scholar | Crossref | Medline3. Coindre, JM, Terrier, P, Bui, NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French federation of cancer centers sarcoma group. J Clin Oncol. 1996;14(3):869-877.
Google Scholar | Crossref | Medline4. Cormier, JN, Pollock, RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54(2):94-109.
Google Scholar | Crossref | Medline | ISI5. Daugaard, S . Current soft-tissue sarcoma classifications. Eur J Cancer (Oxford, England: 1990). 2004;40(4):543-548.
Google Scholar | Crossref6. Kelleher, FC, Viterbo, A. Histologic and genetic advances in refining the diagnosis of “undifferentiated pleomorphic sarcoma”. Cancers (Basel). 2013;5(1):218-233.
Google Scholar | Crossref | Medline7. Judson, I, Verweij, J, Gelderblom, H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415-423.
Google Scholar | Crossref | Medline | ISI8. In, GK, Hu, JS, Tseng, WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017;9(8):533-550.
Google Scholar | SAGE Journals | ISI9. Frezza, AM, Stacchiotti, S, Gronchi, A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017;15(1):109.
Google Scholar | Crossref | Medline10. Cissé, MY, Pyrdziak, S, Firmin, N, et al. Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma. Sci Transl Med. 2020;12(547).
Google Scholar | Crossref | Medline11. Kim, H, Hong, JY, Lee, J, et al. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Ther Adv Med Oncol. 2021;13:1758835921992992.doi: 10.1177/1758835921992992.
Google Scholar | SAGE Journals12. Movva, S, Wen, W, Chen, W, et al. Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget. 2015;6(14):12234-12247.
Google Scholar | Crossref | Medline13. Xu, LB, Zhao, ZG, Xu, SF, et al. The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy. Int J Biol Markers. 2020;35(3):14-22.
Google Scholar | SAGE Journals | ISI14. Lucchesi, C, Khalifa, E, Laizet, Y, et al. Targetable alterations in adult patients with soft-tissue sarcomas: insights for personalized therapy. JAMA Oncol. 2018;4(10):1398-1404.
Google Scholar | Crossref | Medline15. Lawrence, MS, Stojanov, P, Polak, P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218.
Google Scholar | Crossref | Medline | ISI16. Cote, GM, He, J, Choy, E. Next-generation sequencing for patients with sarcoma: a single center experience. Oncologist. 2018;23(2):234-242.
Google Scholar | Crossref | Medline17. Demetri, GD, Baker, LH, Beech, D, et al. Soft tissue sarcoma clinical practice guidelines in oncology. J Natl Comp Cancer Network. 2005;3(2):158-194.
Google Scholar | Medline18. Carmagnani Pestana, R, Groisberg, R, Roszik, J, Subbiah, V. Precision oncology in sarcomas: divide and conquer. JCO Precis Oncol. 2019;3(3):1-16.
Google Scholar19. Zheng, B, Qu, Y, Wang, J, Shi, Y, Yan, W. Pathogenic and targetable genetic alterations in resected recurrent undifferentiated pleomorphic sarcomas identified by targeted next-generation sequencing. Cancer Genomics Proteomics. 2019;16(3):221-228.
Google Scholar | Crossref | Medline20. Casey, DL, Wexler, LH, Pitter, KL, Samstein, RM, Slotkin, EK, Wolden, SL. Genomic determinants of clinical outcomes in rhabdomyosarcoma. Clin Cancer Res. 2020;26(5):1135-1140.
Google Scholar | Crossref | Medline21. Liu, KX, Lamba, N, Hwang, WL, Niemierko, A, DuBois, SG, Haas-Kogan, DA. Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer. 2019;125(8):1357-1364.
Google Scholar | Crossref | Medline22. Pisters, PW, Leung, DH, Woodruff, J, Shi, W, Brennan, MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679-1689.
Google Scholar | Crossref | Medline | ISI23. Stefanovski, PD, Bidoli, E, De Paoli, A, et al. Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur J Surg Oncol. 2002;28(2):153-164.
Google Scholar | Crossref | Medline24. Gaynor, JJ, Tan, CC, Casper, ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol. 1992;10(8):1317-1329.
Google Scholar | Crossref | Medline25. LeVay, J, O'Sullivan, B, et al. Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys. 1993;27(5):1091-1099.
Google Scholar | Crossref | Medline26. Jour, G, Scarborough, JD, Jones, RL, et al. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics. Hum Pathol. 2014;45(8):1563-1571.
Google Scholar | Crossref | Medline27. Harris, MH, DuBois, SG, Glade Bender, JL, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (iCat) study. JAMA Oncol. 2016;2(5):608-615.
Google Scholar | Crossref | Medline28. Groisberg, R, Hong, DS, Holla, V, et al. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017;8(24):39254-39267.
Google Scholar | Crossref | Medline29. Boddu, S, Walko, CM, Bienasz, S, et al. Clinical utility of genomic profiling in the treatment of advanced sarcomas: a single-center experience. JCO Precis Oncol. 2018;2:1-8.
Google Scholar | Medline